CRISPR HIV Cure Shows Phase 1 Success
A Phase 1 CRISPR trial for HIV cure showed 5 out of 12 patients became undetectable while off antiretroviral therapy, according to recent scientific discussions. This represents a potential breakthrough in HIV treatment, moving beyond daily medication management toward actual cures. The results suggest CRISPR gene editing could eliminate HIV from infected cells in some patients.
The clinical trial, identified as EBT-101-001, is the first to test a CRISPR-based therapy against an infectious disease in humans. Sponsored by Excision Biotherapeutics, the study uses CRISPR-Cas9 technology delivered via an adeno-associated virus (AAV9) to find and cut out large sections of the HIV genome from infected cells. This "excise" strategy aims to eliminate the virus's ability to replicate. The primary goal of this initial Phase 1/2 trial was to assess the safety and tolerability of a single intravenous infusion of the therapy, known as EBT-101. Participants were adults with chronic HIV-1 who were on a stable antiretroviral therapy (ART) regimen. The study enrolled participants into different dose-level groups to find a safe and potentially effective amount of the treatment. Safety results from the first cohorts have been positive, with no serious adverse events or dose-limiting toxicities reported. Observed side effects were generally mild and resolved on their own. This initial safety profile is a crucial first step for any new gene-editing treatment. Despite the promising safety data, EBT-101 did not demonstrate a cure at the doses tested. In several participants who paused their standard ART as part of the trial, the virus rebounded, meaning it became detectable again. Researchers believe this is because the therapy did not reach all the cells where HIV lies dormant. However, the trial provided a significant glimmer of hope. One participant who stopped ART maintained viral suppression for 16 weeks, a much longer period than is typical, and also showed a notable drop in their latent HIV reservoir. This suggests the CRISPR therapy had a tangible antiviral effect. Investigators, including Dr. Rachel Presti from Washington University School of Medicine, view these results as a vital first step, providing invaluable insights. The next phase of research will involve testing higher doses of EBT-101 and exploring more efficient delivery methods, such as lipid nanoparticles, to better target the hidden HIV reservoirs.
